Results of a pilot study evaluating a new treatment catheter for transurethral microwave thermotherapy, are reported. The new treatment device is known as Prostaneck and the microwave antenna is located at bladder neck level. Ten patients with symptomatic benign prostatic hyperplasia were enrolled in the study between April and June 1992, following informed consent. Inclusion criteria were as follows: Madsen symptom score >8; peak flow rate <15 ml/s; post voiding residual urine <200 ml. Up to 60 watts energy was released during a single one-hour session, reaching up to 44.5°C in the prostatic urethra and up to 42.5°C in the rectal wall. Follow-up visits were performed 1, 3 and 6 months after treatment and patients evaluated by symptom score, uroflowmetry and transrectal ultrasound sonography. All patients were evaluated for side effects and therapeutic response. No significant short- or long-term morbidity, related to microwave treatment, occurred. The following results were observed 6 months after treatment: symptom score decreased from 14 ± 3.78 to 3.78 ± 4.21 (p < 0.005), peak flow rate increased from 9.24 ± 2.55 to 13.63 ± 6.30 ml/s (p < 0.012); no significant modification in post-voiding residual urine was observed. Significant widening of prostatic urethra was revealed, in most patients, by transrectal ultrasound sonography of the prostate, performed at the 6-month follow-up, and was found to be correlated to flow rate improvement.

PROSTANECK: VALUTAZIONE CLINICA E MECCANISMI D'AZIONE DI UN NUOVO CATETERE PER TERMOTERAPIA TRANSURETRALE

PARADISO GALATIOTO, Giuseppe;TUBARO, ANDREA;
1993-01-01

Abstract

Results of a pilot study evaluating a new treatment catheter for transurethral microwave thermotherapy, are reported. The new treatment device is known as Prostaneck and the microwave antenna is located at bladder neck level. Ten patients with symptomatic benign prostatic hyperplasia were enrolled in the study between April and June 1992, following informed consent. Inclusion criteria were as follows: Madsen symptom score >8; peak flow rate <15 ml/s; post voiding residual urine <200 ml. Up to 60 watts energy was released during a single one-hour session, reaching up to 44.5°C in the prostatic urethra and up to 42.5°C in the rectal wall. Follow-up visits were performed 1, 3 and 6 months after treatment and patients evaluated by symptom score, uroflowmetry and transrectal ultrasound sonography. All patients were evaluated for side effects and therapeutic response. No significant short- or long-term morbidity, related to microwave treatment, occurred. The following results were observed 6 months after treatment: symptom score decreased from 14 ± 3.78 to 3.78 ± 4.21 (p < 0.005), peak flow rate increased from 9.24 ± 2.55 to 13.63 ± 6.30 ml/s (p < 0.012); no significant modification in post-voiding residual urine was observed. Significant widening of prostatic urethra was revealed, in most patients, by transrectal ultrasound sonography of the prostate, performed at the 6-month follow-up, and was found to be correlated to flow rate improvement.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/107737
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact